Pancreatic Cancer Research

ResearcherTianjin Medical University Cancer Institute and HospitalActive in the last 2 years

Chao Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0302-357X; OpenAlex author ID A5103161351. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 2 papers · 2024: 2 papers · 2025: 1 paper · 2026: 3 papers

Papers 9

  1. Mitochondrial Calcium Uniporter Drives Chemoresistance in Pancreatic Cancer via Glutathione-Mediated Stemness Maintenance. Co-author DOI 10.1002/advs.202507346↗
  2. Tumor-Derived Interleukin 35 Promotes Fibrosis in the Tumor Microenvironment of Pancreatic Cancer by Activating Pancreatic Stellate Cells. Co-author DOI 10.1002/advs.202509074↗
  3. Retraction Note: BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis. Co-author DOI 10.1038/s41392-025-02561-9↗
  4. CLT-003 exerts anti-tumor activity in pancreatic cancer by blocking the PI3K/AKT/HIF-1α pathway. Co-author DOI 10.20892/j.issn.2095-3941.2025.0058↗
  5. Correction: BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis. Co-author DOI 10.1038/s41392-023-01721-z↗
  6. BICC1 drives pancreatic cancer stemness and chemoresistance by facilitating tryptophan metabolism. Co-author DOI 10.1126/sciadv.adj8650↗
  7. BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis. Co-author DOI 10.1038/s41392-023-01478-5↗
  8. Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endopl… Co-author DOI 10.1186/s13046-023-02814-x↗
  9. Detection of Circulating Tumor Cells Using Negative Enrichment Immunofluorescence and an In Situ Hybridization System in Pancreatic Cancer. Co-author DOI 10.3390/ijms18040622↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jihui Hao · 8 shared papers, 2017–2026 · strength 1.44
  2. Xiuchao Wang · 8 shared papers, 2017–2026 · strength 1.37
  3. Chongbiao Huang · 6 shared papers, 2023–2026 · strength 1.16
  4. Huizhi Sun · 5 shared papers, 2023–2026 · strength 0.98
  5. Tiansuo Zhao · 5 shared papers, 2023–2026 · strength 0.91
  6. Shengyu Yang · 5 shared papers, 2023–2026 · strength 0.90
  7. Hui Li · 3 shared papers, 2024–2026 · strength 0.66
  8. Yongjie Xie · 3 shared papers, 2023–2026 · strength 0.57
  9. Zengxun Li · 3 shared papers, 2023–2026 · strength 0.56
  10. Song Gao · 4 shared papers, 2017–2024 · strength 0.55
  11. Jing Liu · 3 shared papers, 2023–2024 · strength 0.49
  12. Peng Xie · 2 shared papers, 2024–2026 · strength 0.42
  13. Yukuan Feng · 2 shared papers, 2024–2026 · strength 0.42
  14. Tianxing Zhou · 2 shared papers, 2025–2026 · strength 0.41
  15. Chunhua She · 2 shared papers, 2023–2025 · strength 0.34
  16. Wei Lin · 1 shared paper, 2026 · strength 0.25
  17. Yunzhan Li · 1 shared paper, 2026 · strength 0.24
  18. Zekun Li · 1 shared paper, 2026 · strength 0.24
  19. Xiaofan Guo · 1 shared paper, 2026 · strength 0.24
  20. Junjin Wang · 1 shared paper, 2026 · strength 0.24
  21. Guannan Sheng · 1 shared paper, 2025 · strength 0.18
  22. Liangliang Wu · 1 shared paper, 2025 · strength 0.18
  23. Kaiyuan Wang · 1 shared paper, 2025 · strength 0.18
  24. Bo Ni · 1 shared paper, 2025 · strength 0.18
  25. Song Gao · 1 shared paper, 2025 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.